Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The PROMiSe trial: baseline data review and progress report.

Jerry S Wolinsky1,

  • 1University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA. jswolinsky@aol.com

Multiple Sclerosis (Houndmills, Basingstoke, England)
|June 29, 2004
PubMed
Summary

The PROMiSe trial investigated glatiramer acetate for primary progressive multiple sclerosis (PPMS). Early results show a slower-than-expected disease progression, potentially impacting the trial

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026
Same author

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.

Annals of neurology·2025
Same author

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis.

Annals of clinical and translational neurology·2025
Same author

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

The Lancet. Neurology·2024
Same author

Detection of diffusely abnormal white matter in multiple sclerosis on multiparametric brain MRI using semi-supervised deep learning.

Scientific reports·2024

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Immunology

Background:

  • Primary progressive multiple sclerosis (PPMS) is a debilitating neurological condition.
  • Glatiramer acetate is an immunomodulatory therapy.
  • The PROMiSe trial aimed to assess its efficacy in PPMS.

Purpose of the Study:

  • To evaluate the long-term effects of glatiramer acetate in PPMS patients.
  • To establish baseline characteristics of PPMS patients in a clinical trial setting.
  • To assess disease progression rates and treatment adherence.

Main Methods:

  • Multinational, multicentre, double-blind, placebo-controlled trial.
  • 943 patients with PPMS enrolled, treated for up to 3 years.
  • Clinical and MRI data collected; disease progression and relapse rates monitored.

Related Experiment Videos

Main Results:

  • Low relapse rate (3.9%) confirmed successful exclusion of relapsing MS.
  • Disease progression observed in 16.1% of patients within 12 months (lower than expected).
  • High study withdrawal rate (26.3%), with only 36% discontinuing due to disease progression.

Conclusions:

  • Early findings suggest PPMS natural history may be less aggressive than previously assumed.
  • The observed slow progression rate raises concerns about the trial's ability to demonstrate glatiramer acetate's efficacy.
  • Further analysis is needed to interpret the treatment effect in the context of PPMS natural history.